Dbv Technologies SA DBVT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/17/24 EDT
0.58quote price arrow down-0.0034 (-0.5827%)
Volume
398
Close
0.5835quote price arrow down-0.0075 (-1.269%)
Volume
81,828
52 week range
0.42 - 2.26
Loading...
  • Open0.6141
  • Day High0.6342
  • Day Low0.58
  • Prev Close0.591
  • 52 Week High2.26
  • 52 Week High Date06/21/23
  • 52 Week Low0.42
  • 52 Week Low Date05/13/24

Key Stats

  • Market Cap112.539M
  • Shares Out192.87M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta0.69
  • YTD % Change-38.76

KEY STATS

  • Open0.6141
  • Day High0.6342
  • Day Low0.58
  • Prev Close0.591
  • 52 Week High2.26
  • 52 Week High Date06/21/23
  • 52 Week Low0.42
  • 52 Week Low Date05/13/24
  • Market Cap112.539M
  • Shares Out192.87M
  • 10 Day Average Volume0.15M
  • Dividend-
  • Dividend Yield-
  • Beta0.69
  • YTD % Change-38.76

RATIOS/PROFITABILITY

  • EPS (TTM)-0.42
  • P/E (TTM)-1.40
  • Fwd P/E (NTM)-0.65
  • EBITDA (TTM)-71.881M
  • ROE (TTM)-54.63%
  • Revenue (TTM)14.942M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-531.48%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date07/29/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Dbv Technologies SA

 

Profile

MORE
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from...
Michel De Rosen
Non-Executive Independent Chairman of the Board
Daniel Tasse
Chief Executive Officer, Director
Virginie Boucinha
Chief Financial Officer
Address
177-181 avenue Pierre Brossolette
Montrouge
92120
France